Journal article
Pattern of predictive features of continued cannabis use in patients with recent-onset psychosis and clinical high-risk for psychosis
Nora Penzel, Rachele Sanfelici, Linda A Antonucci, Linda T Betz, Dominic Dwyer, Anne Ruef, Kang Ik K Cho, Paul Cumming, Oliver Pogarell, Oliver Howes, Peter Falkai, Rachel Upthegrove, Stefan Borgwardt, Paolo Brambilla, Rebekka Lencer, Eva Meisenzahl, Frauke Schultze-Lutter, Marlene Rosen, Theresa Lichtenstein, Lana Kambeitz-Ilankovic Show all
SCHIZOPHRENIA | NATURE PORTFOLIO | Published : 2022
Abstract
Continued cannabis use (CCu) is an important predictor for poor long-term outcomes in psychosis and clinically high-risk patients, but no generalizable model has hitherto been tested for its ability to predict CCu in these vulnerable patient groups. In the current study, we investigated how structured clinical and cognitive assessments and structural magnetic resonance imaging (sMRI) contributed to the prediction of CCu in a group of 109 patients with recent-onset psychosis (ROP). We tested the generalizability of our predictors in 73 patients at clinical high-risk for psychosis (CHR). Here, CCu was defined as any cannabis consumption between baseline and 9-month follow-up, as assessed in st..
View full abstractRelated Projects (2)
Grants
Awarded by DFG
Awarded by 7th Framework Programme
Awarded by Australian National Health & Medical Research Council (NHMRC) Senior Principal Research Fellowship
Awarded by NHMRC Program
Funding Acknowledgements
We are grateful to Prof. Vince Calhoun, and Dr. Navin Gupta for sharing their GIG-ICAresults. Further, we want to thank Nils Penzel for his input and methodological help. PRONIA consortium members listed here performed the screening, recruitment, rating, examination and follow-up of the study participants and were involved in implementing the examination protocols of the study, setting up its information technological infrastructure and organizing the flow and quality control of the data analyzed in this article between the local study sites and the central study database. The CIP study is a DFG-funded project (grant agreement No KA 4413/1-1). The PRONIA study is a European Collaboration Project funded under the 7th Framework Programme under grant agreement no 602152. N.P. was supported by a fellowship within the IFI programme of the German Academic Exchange Service (DAAD). R.U. reports grants from Medical Research Council, grants from the National Institute for Health Research and personal fees from Sunovion, outside the submitted work. R.L. participated in advisory boards and received honoraria for talks presented at educational meetings organized by Janssen-Cilag and Otsuka/Lundbeck, outside the submitted work. N.K. and R.S. received honoraria for talks presented at education meetings organized by Otsuka/Lundbeck. C.P. participated in advisory boards for Janssen-Cilag, AstraZeneca, Lundbeck and Servier and received honoraria for talks presented at educational meetings organized by AstraZeneca, Janssen-Cilag, Eli Lilly, Pfizer, Lundbeck, and Shire. C.P. acknowledges support by an Australian National Health & Medical Research Council (NHMRC) Senior Principal Research Fellowship ID: 1105825), a NHMRC Program Grant (ID: 1150083). Open Access funding enabled and organized by Projekt DEAL.